133 related articles for article (PubMed ID: 10845268)
1. The economic burden of hepatitis B in Germany.
Harbarth S; Szucs T; Berger K; Jilg W
Eur J Epidemiol; 2000 Feb; 16(2):173-7. PubMed ID: 10845268
[TBL] [Abstract][Full Text] [Related]
2. Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China.
Lu J; Xu A; Wang J; Zhang L; Song L; Li R; Zhang S; Zhuang G; Lu M
BMC Health Serv Res; 2013 Jan; 13():37. PubMed ID: 23368750
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of hepatitis B infection among patients with diabetes.
Deshpande G; Klink AJ; Shenolikar R; Singer J; Eisenberg Lawrence DF; Krishnarajah G
Hum Vaccin Immunother; 2016 May; 12(5):1132-40. PubMed ID: 27050021
[TBL] [Abstract][Full Text] [Related]
4. Disease Burden from Hepatitis B Virus Infection in Guangdong Province, China.
Xiao J; Lin H; Liu T; Zeng W; Li X; Shao X; Tan Q; Xu Y; Xu X; Zheng H; Ma W
Int J Environ Res Public Health; 2015 Nov; 12(11):14055-67. PubMed ID: 26540065
[TBL] [Abstract][Full Text] [Related]
5. A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients.
Oddone EZ; Cowper PA; Hamilton JD; Feussner JR
Health Serv Res; 1993 Apr; 28(1):97-121. PubMed ID: 8463111
[TBL] [Abstract][Full Text] [Related]
6. How big is the financial burden of hepatitis B to society? A cost-of-illness study of hepatitis B infection in Singapore.
Ong SC; Lim SG; Li SC
J Viral Hepat; 2009 Jan; 16(1):53-63. PubMed ID: 19192158
[TBL] [Abstract][Full Text] [Related]
7. [Economic evaluation and prediction of hepatitis B immunization strategy in Shenzhen, China].
Sun PP; Zhang SX; Xia Y
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Jul; 52(7):743-747. PubMed ID: 29996303
[No Abstract] [Full Text] [Related]
8. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis.
Bloom BS; Hillman AL; Fendrick AM; Schwartz JS
Ann Intern Med; 1993 Feb; 118(4):298-306. PubMed ID: 8420448
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
[TBL] [Abstract][Full Text] [Related]
10. Development of recommendations for control of hepatitis B virus infections: the role of cost analysis.
Margolis HS; Schatz GC; Kane MA
Vaccine; 1990 Mar; 8 Suppl():S81-5; discussion S93-4. PubMed ID: 2139289
[TBL] [Abstract][Full Text] [Related]
11. Cost of acute hepatitis B infection in Swedish adults.
Struve J; Giesecke J
Scand J Infect Dis; 1993; 25(6):693-7. PubMed ID: 8052808
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of the societal costs of hepatitis B in South Korea.
Yang BM; Paik SW; Hahn OS; Yi DH; Choi MS; Payne S
J Gastroenterol Hepatol; 2001 Mar; 16(3):301-8. PubMed ID: 11339422
[TBL] [Abstract][Full Text] [Related]
13. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations.
Margolis HS; Coleman PJ; Brown RE; Mast EE; Sheingold SH; Arevalo JA
JAMA; 1995 Oct; 274(15):1201-8. PubMed ID: 7563509
[TBL] [Abstract][Full Text] [Related]
14. [Financial burden of hepatitis B-related diseases and factors influencing the costs in Shenzhen, China].
Liang S; Zhang SX; Ma QS; Xiao HW; Lü QY; Xie X; Mei SJ; Hu DS; Zhou BP; Li B; Chen JF; Cui FQ; Wang FZ; Liang XF
Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Dec; 31(12):1340-5. PubMed ID: 21223660
[TBL] [Abstract][Full Text] [Related]
15. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis.
Krahn M; Detsky AS
Med Decis Making; 1993; 13(1):4-20. PubMed ID: 8433635
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of economic outcomes of "hepatitis B vaccine event reported by media" in China, 2013].
Zhang SX; Sun PP; Xia Y
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Aug; 52(8):837-841. PubMed ID: 30107719
[No Abstract] [Full Text] [Related]
17. [Economic burden and related factors on inpatients with HBV-related diseases in Shandong province].
Lü JJ; Li RP; Xu AQ; Zhang L; Song LZ; Yan BY; Ji F; Liu JY; Fang XQ; Wang Z; Zhu DW; Zhang GJ; Feng Y; Xiao ZK; Wang J
Zhonghua Liu Xing Bing Xue Za Zhi; 2013 Mar; 34(3):267-72. PubMed ID: 23759235
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of HBV vaccination: A systematic review of recent publications (2000-2013).
La Torre G; Mannocci A; Saulle R; Colamesta V; Meggiolaro A; Mipatrini D; Sinopoli A
Hum Vaccin Immunother; 2016 Sep; 12(9):2299-311. PubMed ID: 27105443
[TBL] [Abstract][Full Text] [Related]
19. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
Hung HF; Chen TH
Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of hepatitis A and B vaccination programme in Germany.
Szucs T
Vaccine; 2000 Feb; 18 Suppl 1():S86-9. PubMed ID: 10683559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
